Hypersensitivity Pneumonitis
Conditions
Keywords
biomarker, prognosis, diagnosis, phenotyping, genotyping
Brief summary
Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data. The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016. Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.
Interventions
None listed
Sponsors
Nils Hoyer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Diagnosis of HP at an MDT conference according to the current international guidelines * Age of 18 years or older * The patients must be capable of giving informed consent
Exclusion criteria
\- Unable to sign informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 3 years | Survival after diagnosis |
| Exposure to inciting antigen (patient reported) | 0 days | Known exposure, as reported by the patient |
| Exposure to inciting antigen (measurable) | 0 days | Measurable exposure, as tested by precipitins |
| Progression free survival | 3 years | Survival without progression |
| Diagnosis of HP | 0 days | MDT-Diagnosis of HP |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pulmonary function test | 3 years | FVC |
| Imaging | 3 years | HRCT scans |
| Quality of life questionnaires | 3 years | SGRQ |
Countries
Denmark
Contacts
Primary ContactNils Hoyer, PhD
Outcome results
None listed